

# AmpliSens® CMV-FRT PCR kit



For Professional Use Only

## Instruction Manual

### KEY TO SYMBOLS USED

	Catalogue number		Caution
	Batch code		Sufficient for
	<i>In vitro</i> diagnostic medical device		Use-by Date
	Version		Consult instructions for use
	Temperature limit		Keep away from sunlight
	Manufacturer	<b>NCA</b>	Negative control of amplification
	Date of manufacture	<b>C-</b>	Negative control of extraction
	Authorized representative in the European Community	<b>C+</b>	Positive control of amplification
		<b>IC</b>	Internal control

### 1. INTENDED USE

AmpliSens® CMV-FRT PCR kit is an *in vitro* nucleic acid amplification test for qualitative detection of human cytomegalovirus (CMV) DNA in the clinical materials (urogenital swabs, urine samples, saliva, whole human blood) using real-time hybridization-fluorescence detection of amplified products.

**NOTE:** The results of PCR analysis are taken into account in complex diagnostics of disease.

### 2. PRINCIPLE OF PCR DETECTION

CMV DNA detection by the polymerase chain reaction (PCR) is based on the amplification of pathogen genome specific region using special primers. In real-time PCR the amplified product is detected using fluorescent dyes. These dyes are usually linked to oligonucleotide probes which bind specifically to the amplified product during thermocycling. The real-time monitoring of the fluorescence intensities during the real-time PCR allows the detection of accumulating product without re-opening the reaction tubes after the PCR run.

AmpliSens® CMV-FRT PCR kit is a qualitative test that contains the Internal Control (Internal Control-FL (IC)). It must be used in the extraction procedure in order to control the extraction process of each individual sample and to identify possible reaction inhibition.

AmpliSens® CMV-FRT PCR kit uses "hot-start", which greatly reduces the frequency of nonspecifically primed reactions. "Hot-start" is guaranteed by separation of nucleotides and Taq-polymerase by using a wax layer or a chemically modified polymerase (TaqF). Wax melts and reaction components mix only at 95 °C. Chemically modified polymerase (TaqF) is activated by heating at 95 °C for 15 min.

The PCR kit contains the system for prevention of contamination by amplicons using the enzyme uracil-DNA-glycosylase (UDG) and deoxyuridine triphosphate. The enzyme UDG recognizes and catalyzes the destruction of the DNA containing deoxyuridine, but has no effect on DNA containing deoxythymidine. Deoxyuridine is absent in the authentic DNA, but is always present in amplicons, because deoxyuridine triphosphate is a part of dNTP mixture in the reagents for the amplification. Due to the deoxyuridine containing contaminating amplicons are sensitive to the destruction by UDG before the DNA-target amplification. So the amplicons cannot be amplified.

The enzyme UDG is thermolabile. It is inactivated by heating at temperature above 50 °C. Therefore, UDG does not destroy the target amplicons which are accumulated during PCR. The results of amplification are registered in the following fluorescence channels.

Table 1

Channel for fluorophore	FAM	JOE
DNA-target	CMV	Internal Control-FL (IC)
Target gene	Pol gene	genetically engineered construction

### 3. CONTENT

AmpliSens® CMV-FRT PCR kit is produced in 1 form: variant FRT-100 F R-V7-F(RG,iQ)-CE.

Variant FRT-100 F includes:

Reagent	Description	Volume, ml	Quantity
PCR-mix-1-FL CMV	clear liquid from colorless to light lilac colour	1.2	1 tube
PCR-mix-2-FRT	colorless clear liquid	0.3	2 tubes
Polymerase (TaqF)	colorless clear liquid	0.03	2 tubes
Positive Control complex (C+)	colorless clear liquid	0.2	1 tube
DNA-buffer	colorless clear liquid	0.5	1 tube
Negative Control (C-)*	colorless clear liquid	1.2	1 tube
Internal Control-FL (IC)**	colorless clear liquid	1.0	1 tube

\* must be used in the extraction procedure as Negative Control of Extraction.

\*\* add 10 µl of Internal Control-FL (IC) during the DNA extraction procedure directly to the sample/lysis mixture (see DNA-sorb-AM K1-12-100-CE, DNA-sorb-B K1-2-100-CE, or RIBO-prep K2-9-Et-100-CE protocols).

Variant FRT-100 F is intended for 110 reactions, including controls.

### 4. ADDITIONAL REQUIREMENTS

- Transport medium.
- DNA extraction kit.
- Disposable powder-free gloves and a laboratory coat.
- Adjustable automatic pipettes from 5 to 20 µl and from 20 to 200 µl).
- Disposable tips with aerosol filters (up to 100 µl) in tube racks.
- Tube racks.
- Vortex mixer.
- PCR box.
- Real-time instruments for example, Rotor-Gene 3000/6000 (Corbett Research, Australia); Rotor-Gene Q (QIAGEN, Germany), iCycler iQ5 (Bio-Rad, USA), Mx3000P (Stratagene, USA)).
- Disposable polypropylene PCR tubes:
  - a) 0.2-ml PCR tubes with optical transparent domed or flat caps if a plate-type instrument is used;
  - b) 0.2-ml PCR tubes with flat caps or strips of four 0.1-ml Rotor-Gene PCR tubes if a rotor-type instrument is used
- Refrigerator for 2–8 °C.
- Deep-freezer at the temperature from minus 24 to minus 16 °C.
- Reservoir for used tips.

### 5. GENERAL PRECAUTIONS

The user should always pay attention to the following:

- Use sterile pipette tips with aerosol barriers and use new tip for every procedure.
- Store all extracted positive material (specimens, controls and amplicons) away from all other reagents and add it to the reaction mix in a distantly separated facility.
- Thaw all components thoroughly at room temperature before starting detection.
- When thawed, mix the components and centrifuge briefly.
- Use disposable protective gloves and laboratory cloths, and protect eyes while samples and reagents handling. Thoroughly wash hands afterward.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all specimens and unused reagents in compliance with local regulations.
- Samples should be considered potentially infectious and handled in a biological cabinet in accordance with appropriate biosafety practices.
- Clean and disinfect all samples or reagent spills using a disinfectant, such as 0.5 % sodium hypochlorite, or other suitable disinfectant.
- Avoid samples and reagents contact with the skin, eyes, and mucous membranes. If these solutions come into contact, rinse the injured area immediately with water and seek medical advice immediately.
- Safety Data Sheets (SDS) are available on request.
- Use of this product should be limited to personnel trained in DNA amplification techniques.
- Workflow in the laboratory must be one-directional, beginning in the Extraction Area and moving to the Amplification and Detection Area. Do not return samples, equipment and reagents to the area in which the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

## 6. SAMPLING AND HANDLING

Obtaining samples of biological materials for PCR-analysis, transportation and storage is described in manufacturer's handbook [1]. It is recommended that this handbook is read before starting work.

**AmpliSens® CMV-FRT** PCR kit is intended for the analysis of DNA extracted by DNA extraction kits from scrapes from the clinical material (mucous membranes of urogenital tract, urine samples, saliva and whole human blood).

## 7. WORKING CONDITIONS

**AmpliSens® CMV-FRT** PCR kit should be used at 18–25 °C.

## 8. PROTOCOL

### 8.1. DNA Extraction

It is recommended to use the following nucleic acid extraction kits:

- **DNA-sorb-AM**, [REF] K1-12-100-CE;
- **DNA-sorb-B**, [REF] K1-2-100-CE – for whole blood samples;
- **RIBO-prep**, [REF] K2-9-Et-100-CE – for whole blood samples - in conjunction with sample pretreatment using **Hemolytic** reagent ([REF] 137-CE).

The DNA extraction of each test sample is carried out in the presence of **Internal Control STI-FL (IC)**.

**NOTE:** Extract DNA according to the manufacturer's protocol.

### 8.2. Preparing PCR

#### 8.2.1 Preparing tubes for PCR

The total reaction volume is 25 µl, the volume of DNA sample is 10 µl.

- 1 Thaw the tube with **PCR-mix-2-FRT**. Vortex the tubes with **PCR-mix-1-FL-F CMV**, **PCR-mix-2-FRT**, and **polymerase (TaqF)** and then centrifuge briefly. Prepare the required number of the tubes for amplification of DNA from test and control samples.
- 2 For N reactions (including 2 controls), add to a new tube:
  - 10\*(N+1) µl of **PCR-mix-1-FL CMV**,
  - 5.0\*(N+1) µl of **PCR-mix-2-FRT** and
  - 0.5\*(N+1) µl of **polymerase (TaqF)**.
 Vortex the tube, then centrifuge it briefly. Transfer 15 µl of the prepared mixture to each tube.

- 3 Using tips with aerosol filter, add 10 µl of **DNA samples** obtained from test or control samples at the DNA extraction stage.
- 4 Carry out the control amplification reactions:
  - NCA** – Add 10 µl of **DNA-buffer** to the tube labeled NCA (Negative Control of Amplification).
  - C+** – Add 10 µl of **Positive Control complex** to the tube labeled C+ (Positive Control of Amplification).
  - C–** – Add 10 µl of the **sample extracted from the Negative Control reagent** to the tube labeled C– (Negative Control of Extraction).

#### 8.2.2. Amplification

1. Create a temperature profile on your instrument as follows:

Table 2

Step	Rotor-type instruments <sup>1</sup>			Plate-type instruments <sup>2</sup>		
	Temperature, °C	Time	Cycles	Temperature, °C	Time	Cycles
1	95	15 min	1	95	15 min	1
2	95	5 s	5	95	5 s	5
	60	20 s		60	20 s	
	72	15 s		72	15 s	
3	95	5 s	40	95	5 s	40
	60	20 s		60	30 s	
		Fluorescence detection			Fluorescence detection	
	72	15 s		72	15 s	

Fluorescent signal is detected in the channels for the FAM and JOE fluorophores (if other tests are conducted simultaneously, the detection in other channels may be done).

2. Adjust the fluorescence channel sensitivity according to the *Important Product Information Bulletin* and Guidelines [2].
3. Insert the tubes into the reaction module of the instrument.
4. Run the amplification program with fluorescence detection.
5. Analyze results after the amplification program is completed.

<sup>1</sup> For example, Rotor-Gene 3000/Rotor-Gene 6000 (Corbett Research, Australia), Rotor-Gene Q (QIAGEN, Germany).

<sup>2</sup> For example, iCycler iQ, iQ5 (Bio-Rad, USA), Mx3000P, Mx3000.

## 9. DATA ANALYSIS

Analysis of results is performed by the software of the real-time PCR instrument used by measuring fluorescence signal accumulation in two channels:

- The signal of the **CMV** DNA amplification product is detected in the channel for the FAM fluorophore;
- The signal of the **IC** amplification product is detected in the channel for the JOE fluorophore.

Results are interpreted by the crossing (or not-crossing) the fluorescence curve with the threshold line set at the specific level that corresponds to the presence (or absence) of a **Ct** value of the DNA sample in the corresponding column of the results grid.

Principle of interpretation is the following:

- **CMV** DNA is **detected** if the **Ct** value is determined in the results grid in the channel for the FAM fluorophore. Moreover, the fluorescence curve of the sample should cross the threshold line in the area of typical exponential growth of fluorescence.
- **CMV** DNA is **not detected** in a sample if the **Ct** value is not determined (absent) in the channel for the FAM fluorophore (fluorescence curve does not cross the threshold line), whereas the **Ct** value in the channel for the JOE fluorophore is less than the boundary **Ct** value specified in the *Important Product Information Bulletin*.
- The result is invalid if the **Ct** value is not determined (absent) in the channel for the FAM fluorophore, whereas the **Ct** value in the channel for the JOE fluorophore is not determined (absent) or greater than the specified boundary **Ct** value. In such cases, the PCR analysis should be repeated.

**NOTE:** Boundary **Ct** values are specified in the *Important Product Information Bulletin* enclosed to the PCR kit. See also Guidelines [2]

**The result of the analysis is considered reliable only if the results obtained for Positive and Negative Controls of amplification as well as for the Negative Control of extraction are correct (see Table 3).**

Table 3

Results for controls			
Control	Stage for control	Ct value in the channel for fluorophore	
		FAM	JOE
C–	DNA extraction	Absent	<boundary value
NCA	PCR	Absent	Absent
C+	PCR	<boundary value	<boundary value

## 10. TROUBLESHOOTING

Results of analysis are not taken into account in the following cases:

1. If the **Ct** value determined for the Positive Control of Amplification (C+) in the channel for the FAM fluorophore is greater than the boundary **Ct** value or absent, the amplification should be repeated for all samples in which **CMV** DNA was not detected.
2. If the **Ct** value is determined for the Negative Control of Amplification (NCA) and/or Negative Control of Extraction (C–) in the channel for the FAM fluorophore, the PCR analysis (beginning with the DNA extraction stage) should be repeated for all samples in which **CMV** DNA was detected.

If you have any further questions or if encounter problems, please contact our Authorized representative in the European Community.

## 11. TRANSPORTATION

**AmpliSens® CMV-FRT** PCR kit should be transported at 2–8 °C for no longer than 5 days.

## 12. STABILITY AND STORAGE

All components of the **AmpliSens® CMV-FRT** PCR kit are to be stored at 2–8 °C when not in use (except for Polymerase (TaqF) and PCR-mix-2-FRT). All components of the **AmpliSens® CMV-FRT** PCR kit are stable until the expiry date stated on the label. The shelf life of reagents before and after the first use is the same, unless otherwise stated.

**NOTE:** Polymerase (TaqF) and PCR-mix-2-FRT are to be stored at the temperature from minus 24 to minus 16 °C when not in use.

**NOTE:** PCR-mix-1-FL **CMV** is to be stored away from light.

## 13. SPECIFICATIONS

### 13.1. Sensitivity

Clinical material	Transport medium	Nucleic acid extraction kit	Sensitivity, GE/ml <sup>3</sup>
Urogenital swabs	Transport Medium for Swabs or Transport Medium with Mucolytic Agent	DNA-sorb-AM	10 <sup>3</sup>
Urine <sup>4</sup>	–	DNA-sorb-AM	2x10 <sup>3</sup>

### 13.2. Specificity

The analytical specificity of **AmpliSens® CMV-FRT** PCR kit is ensured by selection of specific primers and probes as well as stringent reaction conditions. The primers and probes were checked for possible homologies to all sequences published in gene banks by sequence comparison analysis.

Nonspecific reactions were absent while testing human DNA samples and DNA panel of the following microorganisms: *Gardnerella vaginalis*; *Lactobacillus* spp.; *Escherichia coli*; *Staphylococcus* spp.; *Streptococcus* spp.; *Candida albicans*; HSV types 1 and 2; *Mycoplasma hominis*; *Ureaplasma urealyticum*; *Ureaplasma parvum*; *Mycoplasma genitalium*; *Neisseria flava*; *Neisseria subflava*; *Neisseria sicca*; *Neisseria mucosa*; *Neisseria gonorrhoeae*; *Trichomonas vaginalis*; *Treponema pallidum*; *Toxoplasma gondii*; *HPV*.

The clinical specificity of **AmpliSens® CMV-FRT** PCR kit was confirmed in laboratory clinical trials

<sup>3</sup> Genome equivalents (GE) of the pathogen agent per 1 ml of a sample placed in the transport medium.

<sup>4</sup> Pretreatment is required.

## 14. REFERENCES

1. Handbook "Sampling, Transportation, and Storage of Clinical Material for PCR Diagnostics", developed by Federal Budget Institution of Science "Central Research Institute for Epidemiology" of Federal Service for Surveillance on Consumers' Rights Protection and Human Well-Being.
2. Guidelines "Real-Time PCR Detection of STIs and Other Reproductive Tract Infections", developed by Federal Budget Institution of Science "Central Research Institute for Epidemiology" of Federal Service for Surveillance on Consumers' Rights Protection and Human Well-Being, Moscow.

## 15. QUALITY CONTROL

In compliance with Federal Budget Institute of Science "Central Research Institute for Epidemiology" ISO 13485-Certified Quality Management System, each lot of the **AmpliSens® CMV-FRT** PCR kit has been tested against predetermined specifications to ensure consistent product quality.

List of Changes Made in the Instruction Manual

VER	Location of changes	Essence of changes
23.06.11 RT	Cover page, text	The name of Institution was changed to Federal Budget Institution of Science "Central Research Institute for Epidemiology"
02.07.15 PM	Through the text	Corrections in accordance with the template
	8.1. DNA Extraction	The chapter was completed, DNA-sorb-B, RIBO-prep and Hemolytic were added for extraction of whole blood samples.
	9. Data analysis	The section was rewritten
26.12.17 PM	13. Specifications	The list of microorganisms, on which the specificity was proved, was added.
	3. Content	The color of the reagent was specified
05.12.18 PM	2. Principle of PCR detection	The table with targets and the information about the enzyme UDG were added
	Through the text	The text formatting was changed
27.02.20 PM	Footer	The phrase "Not for use in the Russian Federation" was added
26.10.20 MM	Footer, Content	<b>REF</b> R-V7(RG)-CE was deleted
01.03.21 KK	—	The name, address and contact information for Authorized representative in the European Community was changed

**AmpliSens®**



Ecoli Dx, s.r.o., Purkyňova 74/2  
110 00 Praha 1, Czech Republic  
Tel.: +420 325 209 912  
Cell: +420 739 802 523



Federal Budget Institute of  
Science "Central Research  
Institute for Epidemiology"  
3A Novogireevskaya Street  
Moscow 111123 Russia